Business context and reporting period
This is Petra Acquisition, Inc.’s unaudited Form 10-Q for the quarter and nine months ended September 30, 2021—not an operating-company quarterly report for Revelation Biosciences, Inc. Petra was a blank-check company with no operations or revenue; it had agreed on August 29, 2021 to merge with Revelation Biosciences. The merger had not closed by September 30.
Financial results and position
- Revenue: None. Petra stated it would not generate operating revenue before a business combination.
- Third-quarter 2021: General and administrative expense was $844,531; net loss was $757,638, or $0.42 per nonredeemable share. A $85,040 gain from the change in warrant fair value and $1,853 interest income partly offset expenses. In Q3 2020, net loss was $868.
- Nine months ended September 30, 2021: General and administrative expense was $2,155,418 and net loss was $910,588, or $0.50 per nonredeemable share. A $1,256,462 warrant fair-value gain substantially offset expenses. In the comparable 2020 period, net loss was $8,549; the periods are not directly comparable given the company’s IPO and development stage.
- Cash flow: Nine-month operating cash outflow was $499,916; investing cash inflow was $488,182, mainly proceeds from marketable securities. Financing cash flow was zero, and cash declined by $11,734 to zero.
- Liquidity and liabilities at September 30: Current assets were $39,083, including $19,749 in marketable securities and no cash; current liabilities were $3,737,529, including $1,594,113 in accounts payable and accrued liabilities and $2,143,416 in warrant liability. Working capital deficit was approximately $3.698 million. The trust account held $73,516,414, largely restricted for a business combination or shareholder redemptions. Deferred underwriting commissions were $2,911,260.
- Debt and margins: The filing reports no long-term debt and no revenue, so operating margins are not meaningful. A September 2021 affiliate promissory note for up to $850,000 had no balance drawn at quarter-end.
Material changes, outlook, and risks
- Petra’s reported expenses and losses rose versus the 2020 comparison, while warrant fair-value gains reduced the 2021 reported net loss. The warrant liability is measured using Level 3 inputs and can cause earnings volatility.
- The merger agreement contemplated issuing 10.5 million Petra shares to Revelation’s owners; existing Petra shareholders would retain approximately 14% of post-merger shares before considering redemptions. The filing describes the transaction as a reverse recapitalization for accounting purposes.
- On October 8, 2021, shareholders extended the business-combination deadline from October 13 to November 13, 2021, with further extension options. The filing text states one option date as January 13, 2021, which appears inconsistent and should be checked against the filed amendment.
- On October 13, 2021, three promissory notes totaling up to $750,000 were issued; they accrue interest at 2% per month and are repayable upon a business combination. The previously undrawn Pine Valley note was cancelled that day.
- Management said available funds and borrowing capacity were expected to support completion efforts, but warned that additional financing could be needed and that failure to complete a business combination could require liquidation. The company’s deadline and ability to close the proposed transaction were central risks.
- Management concluded disclosure controls were ineffective because of a material weakness associated with the prior restatement of derivative warrants as liabilities. Remediation was planned, with no assurance it would be effective. The filing reported no material change in previously disclosed risk factors and no pending material legal proceedings.
Important facts to verify
- Confirm the correct registrant and period: this filing is Petra Acquisition’s 2021 Q3 10-Q, not Revelation Biosciences’ operating-company 10-Q.
- Check the merger’s closing status, shareholder approvals, redemptions, financing, and final ownership dilution.
- Verify the extended business-combination deadline and the apparent date error for the further extension option.
- Reconcile the trust-account amount: the balance sheet reports $73,516,414, while the MD&A gives $73,514,561.
- Review the material weakness, restatement history, and progress on controls remediation.
- Assess accrued legal fees, deferred underwriting and advisory fees, and the terms and drawdowns of post-quarter promissory notes.